This article was originally published in The Gray Sheet
Department of Justice sends a letter to Medtronic Nov. 16 requesting any information that the firm also is providing to the Securities and Exchange Commission related to SEC's investigation into possible violations of the U.S. Foreign Corrupt Practices Act, the firm notes in its Dec. 4 quarterly SEC filing. The firm says it is cooperating with DoJ and SEC. In September, SEC notified Stryker, Zimmer, Biomet, Smith & Nephew and Medtronic that it is investigating potential corrupt practices related to the companies' sales of devices in an unspecified number of countries including Greece, Poland and Germany (1"The Gray Sheet" Oct. 22, 2007, p. 10)
You may also be interested in...
Federal prosecutors have begun targeting medical device companies in Foreign Corrupt Practices Act investigations
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.